LifeSteps Financial Inc. Purchases 91 Shares of Eli Lilly and Company $LLY

LifeSteps Financial Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 31.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 382 shares of the company’s stock after acquiring an additional 91 shares during the quarter. LifeSteps Financial Inc.’s holdings in Eli Lilly and Company were worth $298,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Nelson Capital Management LLC boosted its position in shares of Eli Lilly and Company by 1.3% in the second quarter. Nelson Capital Management LLC now owns 3,713 shares of the company’s stock valued at $2,894,000 after acquiring an additional 47 shares during the period. Lansing Street Advisors raised its stake in Eli Lilly and Company by 24.2% in the second quarter. Lansing Street Advisors now owns 1,793 shares of the company’s stock valued at $1,397,000 after purchasing an additional 349 shares in the last quarter. Northern Financial Advisors Inc raised its stake in Eli Lilly and Company by 11.2% in the second quarter. Northern Financial Advisors Inc now owns 2,232 shares of the company’s stock valued at $1,740,000 after purchasing an additional 225 shares in the last quarter. Winthrop Advisory Group LLC raised its stake in Eli Lilly and Company by 1.2% in the second quarter. Winthrop Advisory Group LLC now owns 1,706 shares of the company’s stock valued at $1,330,000 after purchasing an additional 21 shares in the last quarter. Finally, Puzo Michael J raised its stake in Eli Lilly and Company by 80.2% in the second quarter. Puzo Michael J now owns 4,581 shares of the company’s stock valued at $3,571,000 after purchasing an additional 2,039 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Guggenheim lowered their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Morgan Stanley lowered their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Cantor Fitzgerald lowered their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $938.94.

Insider Activity

In other news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 0.1%

LLY stock opened at $844.30 on Wednesday. The company has a market capitalization of $799.09 billion, a PE ratio of 55.18, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company’s 50 day moving average price is $736.97 and its two-hundred day moving average price is $766.03. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% compared to the same quarter last year. During the same period last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.